Part-Time

Office Coordinator

BreezeBio

BreezeBio

51-200 employees

CRISPR gene therapies delivered by nanoparticles

No salary listed

Daly City, CA, USA + 1 more

More locations: San Bruno, CA, USA

In Person

On-site roles in California; no remote work.

Category
Administrative & Executive Assistance (1)
Required Skills
Communications

Get referred to BreezeBio

See people who can refer or advise you

Requirements
  • Bachelor’s degree preferred
  • 2+ years of experience in an administrative, office coordinator, or executive assistant role
  • Strong organizational and time-management skills with exceptional attention to detail
  • Excellent written and verbal communication skills
  • Ability to multitask, prioritize, and work independently in a fast-paced environment
  • High level of professionalism, discretion, and confidentiality
  • Proficiency with standard office tools (Google Workspace, Microsoft Office, etc.)
  • Work authorization in the United States is required
Responsibilities
  • Provide high-level, comprehensive administrative support to the CEO and Executive Leadership Team (ELT), including complex calendaring, meeting coordination, and travel planning
  • Prepare detailed agendas, briefing materials, and follow-ups for executive meetings
  • Serve as a liaison between executives and internal/external stakeholders, maintaining professionalism and confidentiality
  • Draft, edit, and manage communications on behalf of leadership
  • Oversee daily office operations to ensure a productive, organized, and efficient work environment
  • Coordinate company meetings, events, and team gatherings
  • Manage office vendors, supplies, and facilities-related needs
  • Support cross-functional initiatives across HR, IT, and Operations
  • Maintain and improve office processes, workflows, and administrative systems
  • Ensure office policies and procedures are followed and continuously optimized
  • Assist with project coordination across departments, tracking timelines and deliverables
  • Support leadership with ad hoc projects, reporting, and organizational initiatives
  • Help streamline internal communications and operational processes

BreezeBio develops gene therapies and gene-editing solutions using a CRISPR delivery system built from engineered CRISPR components and a proprietary polymer nanoparticle library. It packages CRISPR components into polymer nanoparticles that deliver Cas9 and guide RNAs to target cells, enabling tissue-specific gene edits. The company differentiates itself by combining in-house polymer nanoparticle technology with component-level CRISPR engineering, supported by proof-of-concept data and industry partnerships. Its goal is to commercialize the delivery platform and resulting therapeutics through licensing, partnerships, and direct sales to medical and healthcare clients.

Company Size

51-200

Company Stage

Series B

Total Funding

$118.5M

Headquarters

Brisbane, California

Founded

2016

Get referred to BreezeBio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • $60 million Series B closed February 25, 2026 funds IND-enabling BRZ-101 work.
  • July 21, 2026 Ligachem deal expands BreezeBio into cancer vaccine research.
  • July 2026 advisory board adds ex-Capstan, Eli Lilly, and immunotherapy veterans.

What critics are saying

  • BRZ-101 faces first-human failure risk in 2027 if IND studies disappoint.
  • Genentech collaboration concentration exposes BreezeBio to one partner's priorities and milestone timing.
  • A negative autoimmune readout kills NanoGalaxy's investor narrative and future financing.

What makes BreezeBio unique

  • NanoGalaxy targets immune, cardiac, pulmonary, and CNS tissues with one polymer platform.
  • BRZ-101 combines mRNA autoantigens and tolerogenic cofactors for antigen-specific immune tolerance.
  • Genentech collaborations and Ligachem research validate BreezeBio's delivery science across multiple disease areas.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

0%
BioWorld
Jul 21st, 2026
Breezebio and Ligachem partner on cancer vaccine research.

Breezebio and Ligachem partner on cancer vaccine research. July 21, 2026 Breezebio Inc. (formerly Genedit Inc.) has entered into a joint research agreement with Ligachem Biosciences Inc. to develop innovative cancer vaccine therapies.

Associated Press
May 26th, 2026
BreezeBio forms scientific advisory board to advance type 1 diabetes therapy and NanoGalaxy platform

BreezeBio, formerly GenEdit, has formed a Scientific Advisory Board to guide development of its precision genetic medicine pipeline and NanoGalaxy platform. The South San Francisco-based company is advancing BRZ-101, its lead programme for type 1 diabetes, into IND-enabling studies. BRZ-101 delivers mRNA-encoded autoantigens and tolerogenic co-factors to antigen-presenting cells, aiming to induce regulatory T cells that suppress autoimmune responses whilst preserving broader immune function. The NanoGalaxy platform has demonstrated targeted delivery to immune, cardiac, pulmonary and central nervous systems. The inaugural SAB includes experts from academia and industry, including former executives from Capstan Therapeutics, Eli Lilly, and leaders in bioengineering and immunotherapy development. BreezeBio is developing a pipeline focused on autoimmune diseases and oncology.

Informa TechTarget
Feb 25th, 2026
BreezeBio raises $60M Series B to develop precision genetic medicines for autoimmune diseases

BreezeBio, a South San Francisco-based genetic medicines startup, has raised $60 million in a Series B round co-led by Yuanta Investment and DSC Investment. The company, formerly known as GenEdit, has refocused from developing delivery technology to creating its own treatments for autoimmune diseases and oncology. The startup's proprietary NanoGalaxy technology uses specialised polymer nanoparticles to deliver genetic cargo to specific organs with precision. BreezeBio has previously secured collaboration deals with Sarepta Therapeutics, Editas Medicine and Genentech. Its lead programme, BRZ-101, aims to suppress the autoimmune response in Type 1 diabetes by delivering blueprints for antigens that promote immune tolerance. The therapy is advancing into final preclinical studies this year before human testing begins.

Breeze Bio
Feb 25th, 2026
BreezeBio (Formerly GenEdit) Announces Series B Financing to Advance Internal Pipeline of Precision Genetic Medicines

BreezeBio (formerly GenEdit) announces Series B financing to advance internal pipeline of precision genetic medicines. February 25, 2026 - New therapeutics in development for autoimmune disease and oncology - Lead therapeutic BRZ-101 designed to restore immune tolerance in type 1 diabetes, advancing into IND-enabling studies - Expanding platform capabilities for NanoGalaxy(R), including targeted delivery for in vivo CAR SOUTH SAN FRANCISCO, Calif., February 25, 2026 - Breeze Bio, Inc., formerly known as GenEdit, today announced the close of $60 million in Series B financing to advance its first internal therapeutic programs toward the clinic and to continue expansion of the company's NanoGalaxy delivery platform. The new BreezeBio name reflects the company's momentum in translating powerful delivery technologies into practical, scalable genetic medicines with curative potential. "Now that we can deliver genetic payloads to the right cells with precision, we are building genetic medicines designed to make a real difference for patients," said Kunwoo (Ryan) Lee, Ph.D., Chief Executive Officer of BreezeBio. "We've completed our transition from a delivery platform to a therapeutics company, and this financing allows us to advance our first internal programs toward the clinic while continuing to expand the reach of NanoGalaxy." The company's lead therapeutic candidate, BRZ-101, is a novel immune modulation therapy designed to restore tolerance in type 1 diabetes. The therapy delivers autoantigens encoded by mRNA and tolerogenic co-factors to antigen-presenting cells, which in turn present the antigens to T cells in the context of tolerance. The process induces antigen-specific regulatory T cells (Tregs) that block the autoimmune response precisely without affecting the functioning of the immune system. In preclinical testing, BRZ-101 induced antigen-specific immune tolerance in multiple models of autoimmune disease, including the NOD mouse model of diabetes, and was well tolerated in mice and non-human primates. The company is advancing BRZ-101 into IND-enabling studies. "BreezeBio is solving one of the most significant challenges in gene therapy, targeted delivery, and in doing so is helping define the next generation of genetic medicines," said Vincent Jeong, Managing Director at Yuanta Investment, manager of the Ministry of Health, and lead investor in the Series B financing. "With platform validation through the company's strategic collaboration and milestone achievement with a global biotech partner and clear progress toward clinical development, BreezeBio is approaching an important inflection point as it advances a differentiated internal pipeline designed to address significant unmet needs in autoimmune and other serious diseases. We believe BreezeBio is positioned to become a global genetic medicines developer, and Yuanta is committed to supporting that journey." The engine for BreezeBio's therapeutic programs is the company's proprietary NanoGalaxy platform, which has demonstrated targeted delivery to the immune, cardiac, pulmonary, and central nervous systems based on the physiochemical properties of the polymers that encapsulate the payloads and form the nanoparticles. In addition, BreezeBio is expanding the platform with ligands conjugated to the nanoparticles for additional tissue and cell specificity, including delivery to T cells to enable in vivo CAR-T therapeutic development. In parallel with its internal programs, BreezeBio continues to advance its multi-year collaboration and licensing agreement with Genentech, a member of the Roche Group. Following the initial milestone achievement and associated payment last year, R&D activities under the collaboration continue to progress. The Series B financing is led by new investors, Yuanta Investment and DSC Investment, with participation from SV investment, Kiwoom Investment, STIC Ventures, Top Harvest Capital, and others. Existing investors, including DAYLI Partners, Pathway Investment, Loftyrock Investment, Korea Investment Partners, WOORI Venture Partners, KDB Silicon Valley, and ACVC Partners also participated. About BreezeBio BreezeBio is a biotechnology company developing genetic medicines enabled by precise, non-viral delivery across biologically relevant tissues. Using its proprietary NanoGalaxy(R) platform, BreezeBio engineers nanoparticles designed to deliver genetic payloads, including mRNA, to specific cell types, with demonstrated delivery to immune cells as well as select tissues in the heart, lung, and central nervous system. The company is advancing an internal therapeutic pipeline focused on autoimmune diseases and oncology, led by BRZ-101 to restore immune tolerance in type 1 diabetes. BreezeBio is headquartered in California in the South San Francisco area. For more information, visit www.breezebio.com. Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., [email protected]

Maeil Business Newspaper
Nov 14th, 2024
Korea's No. 1 Economic Media

GenEdit, a gene therapy development company, announced on the 14th that it has appointed Dr. Rodrigo Mora as its chief scientific officer (CSO) to expand the development of tissue-specific gene therapy using the Nano Galaxy platform.